Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Neutral

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Strong Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Buy

A

Jazz Pharmaceuticals, Inc. (JAZZ)

Pharmaceutical Preparations

https://www.jazzpharmaceuticals.com

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

FIFTH FLOOR, WATERLOO EXCHANGE, WATERLOO ROAD
DUBLIN, L2

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/01/2007

Market Cap

6,871,620,713

Shares Outstanding

62,960,000

Weighted SO

62,956,913

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

INCY --.--%

ALNY --.--%

UTHR --.--%

RARE --.--%

APLS --.--%

BMRN --.--%

SGEN --.--%

EXEL --.--%

HALO --.--%

Beta

0.5830

Last Div

0.0000

Range

99.06-146.7

Chg

1.2750

Avg Vol

767240

Mkt Cap

6871620713

Exch

NASDAQ

Country

IE

Phone

353 1 634 7800

DCF Diff

-654.6471

DCF

774.3221

Div Yield

0.0000

P/S

1.7575

EV Multiple

8.7546

P/FV

1.8597

Div Yield %

0.0000

P/E

17.7178

PEG

1.1198

Payout

0.2843

Current Ratio

2.2467

Quick Ratio

1.8980

Cash Ratio

0.8328

DSO

65.1640

DIO

225.7319

Op Cycle

290.8959

DPO

40.3971

CCC

250.4988

Gross Margin

0.7756

Op Margin

0.1663

Pretax Margin

0.0761

Net Margin

0.1010

Eff Tax Rate

-0.3338

ROA

0.0348

ROE

0.1076

ROCE

0.0663

NI/EBT

1.3281

EBT/EBIT

0.4573

EBIT/Rev

0.1663

Debt Ratio

0.5038

D/E

1.5213

LT Debt/Cap

0.5755

Total Debt/Cap

0.6034

Int Coverage

3.9350

CF/Debt

0.1875

Equity Multi

3.0197

Rec Turnover

5.6013

Pay Turnover

9.0353

Inv Turnover

1.6170

FA Turnover

16.1282

Asset Turnover

0.3441

OCF/Share

17.0655

FCF/Share

16.6140

Cash/Share

31.5003

OCF/Sales

0.2745

FCF/OCF

0.9735

CF Coverage

0.1875

ST Coverage

1.7226

CapEx Coverage

37.7911

Div&CapEx Cov

7.6283

P/BV

1.8597

P/B

1.8597

P/S

1.7575

P/E

17.7178

P/FCF

6.5775

P/OCF

6.5205

P/CF

6.5205

PEG

1.1198

P/S

1.7575

EV Multiple

8.7546

P/FV

1.8597

DPS

0.0000

Latest Headlines (EST)

The Motley Fool Jan 22, 05:16 2 Incredible Growth Stocks That Are Screaming Buys for 2024 The Motley Fool Jan 13, 05:06 4 Remarkable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip MarketWatch Dec 30, 07:02 20 midcap stocks with 2024 upside ranging up to 62%, according to analysts MarketWatch Dec 26, 13:02 20 midcap stocks with 2024 upside ranging up to 62%, according to analysts MarketWatch Dec 26, 13:02 20 midcap stocks with 2024 upside ranging up to 62%, according to analysts The Motley Fool Dec 20, 05:21 3 No-Brainer Stocks to Buy With $500 Right Now Zacks Investment Research Nov 22, 14:15 Pot Stocks: Values or Traps? The Motley Fool Nov 22, 05:30 3 Biotech Stocks That Could Be Millionaire Makers The Motley Fool Nov 15, 05:21 3 No-Brainer Stocks to Buy With $200 Right Now

Revenue Product Segmentation